A tighter archive for life-science signals.
Search once, then narrow by source or topic.
Merck KGaA drops two cancer trials on assets from SpringWorks deal
Merck KGaA drops two cancer trials on assets from SpringWorks deal
Novo Nordisk details Irish expansion; EuroAPI’s challenges continue
Novo Nordisk details Irish expansion; EuroAPI’s challenges continue
How hospitals have shifted from experimenting with AI to justifying its cost
How hospitals have shifted from experimenting with AI to justifying its cost
Yale’s Craig Crews builds model to guide biotech startups out of academia’s ‘valley of death’
Yale’s Craig Crews builds model to guide biotech startups out of academia’s ‘valley of death’
FDA's top operating official Butler to retire, deputy to take over in April
FDA's top operating official Butler to retire, deputy to take over in April
Bayer continues trimming workforce; AnaptysBio's spinoff is named
Bayer continues trimming workforce; AnaptysBio's spinoff is named
BIO chief still backs FDA's Makary despite 'head-scratcher' decisions
BIO chief still backs FDA's Makary despite 'head-scratcher' decisions
Sanofi licenses Sino Biopharm’s transplant drug for $135M upfront
Sanofi licenses Sino Biopharm’s transplant drug for $135M upfront
UCB boards T cell engager train in $60M upfront deal with Antengene
UCB boards T cell engager train in $60M upfront deal with Antengene
Blackstone to support Teva on Sanofi-partnered TL1A with $400M
Blackstone to support Teva on Sanofi-partnered TL1A with $400M
Moderna will pay $950M to settle Covid vaccine patent claims with Arbutus, Roivant
Moderna will pay $950M to settle Covid vaccine patent claims with Arbutus, Roivant
Old school healthcare is warming up to tech
Old school healthcare is warming up to tech
Prime Medicine reverses course to seek FDA approval of shelved therapy
Prime Medicine reverses course to seek FDA approval of shelved therapy
After years of dispute with FDA, Vanda will get a public hearing for jet lag drug
After years of dispute with FDA, Vanda will get a public hearing for jet lag drug
Kyowa Kirin ends OX40 trials after Amgen balked, safety concern
Kyowa Kirin ends OX40 trials after Amgen balked, safety concern
FDA explains how some copycat drugs can still win three years of exclusivity
FDA explains how some copycat drugs can still win three years of exclusivity
EveryOne Medicines shuts down, ending custom cure venture that banked on new FDA pathway
EveryOne Medicines shuts down, ending custom cure venture that banked on new FDA pathway
Prolium's $50M Series A raise; COUR Pharma touts liver drug follow-up
Prolium's $50M Series A raise; COUR Pharma touts liver drug follow-up
Brand directory, kept in view
A rolling strip of the companies, platforms, CROs and device makers that show up across the coverage.
Open about page